SYNEOS HEALTH COMMERCIAL FRANCE : revenue, balance sheet and financial ratios

SYNEOS HEALTH COMMERCIAL FRANCE is a French company founded 12 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in PARIS 14 (75014), this company of category ETI shows in 2024 a revenue of 7.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SYNEOS HEALTH COMMERCIAL FRANCE (SIREN 802771501)
Indicator 2024 2023 2022 2021 2020 2019 2018
Revenue 7 174 965 € 3 447 371 € 3 217 916 € 1 577 945 € 2 214 742 € 2 681 489 € 745 602 €
Net income 85 295 € 41 353 € 31 359 € 135 670 € 106 324 € 140 602 € -73 418 €
EBITDA 114 478 € 101 621 € 50 362 € 175 495 € 80 882 € 134 627 € -72 873 €
Net margin 1.2% 1.2% 1.0% 8.6% 4.8% 5.2% -9.8%

Revenue and income statement

In 2024, SYNEOS HEALTH COMMERCIAL FRANCE achieves revenue of 7.2 M€. Over the period 2018-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +45.8%. Vs 2023, growth of +108% (3.4 M€ -> 7.2 M€). After deducting consumption (0 €), gross margin stands at 7.2 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 114 k€, representing 1.6% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 85 k€, i.e. 1.2% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

7 174 965 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

7 174 965 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

114 478 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

123 572 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

85 295 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

1.6%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 115%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 21%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 5.7 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 1.3% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

115.041%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

21.49%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

1.329%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

5.698

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

28.3%

Solvency indicators evolution
SYNEOS HEALTH COMMERCIAL FRANCE

Sector positioning

Debt ratio
115.04 2024
2022
2023
2024
Q1: 0.0
Med: 4.27
Q3: 43.96
Watch +34 pts over 3 years

In 2024, the debt ratio of SYNEOS HEALTH COMMERCIAL ... (115.04) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.

Financial autonomy
21.49% 2024
2022
2023
2024
Q1: 14.64%
Med: 38.36%
Q3: 60.56%
Average -8 pts over 3 years

In 2024, the financial autonomy of SYNEOS HEALTH COMMERCIAL ... (21.5%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
5.7 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.0 years
Q3: 1.09 years
Average +19 pts over 3 years

In 2024, the repayment capacity of SYNEOS HEALTH COMMERCIAL ... (5.70) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 185.19. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 7.4x. Operating income very largely covers interest expenses: high safety margin.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

185.189

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

7.383

Liquidity indicators evolution
SYNEOS HEALTH COMMERCIAL FRANCE

Sector positioning

Liquidity ratio
185.19 2024
2022
2023
2024
Q1: 132.74
Med: 202.27
Q3: 325.9
Average +17 pts over 3 years

In 2024, the liquidity ratio of SYNEOS HEALTH COMMERCIAL ... (185.19) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
7.38x 2024
2022
2023
2024
Q1: 0.0x
Med: 0.41x
Q3: 6.25x
Excellent +12 pts over 3 years

In 2024, the interest coverage of SYNEOS HEALTH COMMERCIAL ... (7.4x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 32 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 16 days. The company must finance 16 days of gap between collections and payments. Overall, WCR represents 36 days of revenue, i.e. 726 k€ to permanently finance. Notable WCR improvement over the period (-46%), freeing up cash.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

725 963 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

32 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

16 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

36 j

WCR and payment terms evolution
SYNEOS HEALTH COMMERCIAL FRANCE

Positioning of SYNEOS HEALTH COMMERCIAL FRANCE in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of SYNEOS HEALTH COMMERCIAL FRANCE is estimated at 512 729 € (range 272 973€ - 1 586 395€). With an EBITDA of 114 478€, the sector multiple of 0.7x is applied. The price/revenue ratio is 0.21x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
124 transactions
272k€ 512k€ 1586k€
512 729 € Range: 272 973€ - 1 586 395€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
114 478 € × 0.7x
Estimation 80 579 €
38 093€ - 293 279€
Revenue Multiple 30%
7 174 965 € × 0.21x
Estimation 1 528 084 €
828 644€ - 4 628 591€
Net Income Multiple 20%
85 295 € × 0.8x
Estimation 70 071 €
26 670€ - 255 891€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare SYNEOS HEALTH COMMERCIAL FRANCE with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about SYNEOS HEALTH COMMERCIAL FRANCE

What is the revenue of SYNEOS HEALTH COMMERCIAL FRANCE ?

The revenue of SYNEOS HEALTH COMMERCIAL FRANCE in 2024 is 7.2 M€.

Is SYNEOS HEALTH COMMERCIAL FRANCE profitable?

Yes, SYNEOS HEALTH COMMERCIAL FRANCE generated a net profit of 85 k€ in 2024.

Where is the headquarters of SYNEOS HEALTH COMMERCIAL FRANCE ?

The headquarters of SYNEOS HEALTH COMMERCIAL FRANCE is located in PARIS 14 (75014), in the department Paris.

Where to find the tax return of SYNEOS HEALTH COMMERCIAL FRANCE ?

The tax return of SYNEOS HEALTH COMMERCIAL FRANCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SYNEOS HEALTH COMMERCIAL FRANCE operate?

SYNEOS HEALTH COMMERCIAL FRANCE operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.